A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Key facts

Study ID

NCT02804399

Run by

Pfizer

People needed

12

Starts

2016-07-01

Expected to finish

2016-10-01

Last updated by the study team

2019-01-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy female subjects of non-childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

You may not qualify if…

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
• Any condition possibly affecting drug absorption
• Positive urine drug screen
• History of HIV, Hep B or Hep C
• History of regular alcohol consumption
• History of cardiac arrhythmia, history of AV block, history of symptomatic bradycardia, history of QTc prolongation
• History of pancreatitis or hyperlipidemia, elevated lipase

Where it is running

• Pfizer New Haven Clinical Research Unit — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.